Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination

NEWTOWN, Pa., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
September 07, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences

NEWTOWN, Pa., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
August 15, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

NEWTOWN, Pa., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
August 11, 2016 09:20 ET | Source: Onconova Therapeutics

Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2016 Financial Results

NEWTOWN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
August 01, 2016 08:01 ET | Source: Onconova Therapeutics

Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million

NEWTOWN, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on discovering...
July 27, 2016 09:20 ET | Source: Onconova Therapeutics

Onconova Announces Expiration of Oversubscribed Rights Offering

NEWTOWN, Pa., July 27, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on discovering...
July 22, 2016 17:52 ET | Source: Onconova Therapeutics

Onconova Adjusts Pricing of Rights Offering

NEWTOWN, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on discovering...
July 19, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Announces Enrollment of First Patient in Japan by SymBio

NEWTOWN, Pa., July 19, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products...
July 08, 2016 09:20 ET | Source: Onconova Therapeutics

Onconova Announces Commencement of Subscription Period for Previously Announced Rights Offering

NEWTOWN, Pa., July 08, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on discovering...
July 01, 2016 07:01 ET | Source: Onconova Therapeutics

Onconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016

NEWTOWN, Pa., July 01, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or the “Company”), a Phase 3 clinical-stage biopharmaceutical company focused on...